Day: June 13, 2025

Glassbeam Awarded FedRAMP Authorization for its SAAS analytics solution for connected medical systems by the U.S. Department of Veterans Affairs.

Staff June 13, 2025

This designation enables Glassbeam to support federal government agency customers increase uptime for all MRI and CT scanners and avoid...

XtalPi Announces Strategic Acquisition of Liverpool ChiroChem (LCC), Unlocking Unprecedented Power in Chemical Space Exploration

Staff June 13, 2025

CAMBRIDGE, Mass. and LIVERPOOL, United Kingdom, June 13, 2025 /PRNewswire/ -- XtalPi, a leading life sciences and new materials R&D...

Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan

Staff June 13, 2025

Accelerating the Growth of Globally Active Drug-Discovery Startups from Japan TOKYO, June 13, 2025 /PRNewswire/ -- Mitsubishi Research Institute, Inc....

Day: June 13, 2025

Glassbeam Awarded FedRAMP Authorization for its SAAS analytics solution for connected medical systems by the U.S. Department of Veterans Affairs.

XtalPi Announces Strategic Acquisition of Liverpool ChiroChem (LCC), Unlocking Unprecedented Power in Chemical Space Exploration

Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan

MENU – ORDER AI Announces Global Expansion with New Multilingual Capabilities, Supporting WHO Guidance on Dietary Needs for GLP-1 Users

AMEEREX Signs MOU to Acquire 45.6 million-Ounce Silver-Gold Project in Nevada, Expanding Its North American Precious-Metals Portfolio

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company’s RXR agonist compound IRX4204 has synergistic efficacy against human multiple myeloma

You may have missed